| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 特色原料药及中间体(元) | 731,532,152.21 | - | 693,095,401.74 | - | 777,583,418.85 |
| 贸易类及其他(元) | 62,088,187.19 | 65,288,585.50 | 79,192,196.76 | 127,612,369.46 | 72,782,229.75 |
| 专利药原料药及中间体(元) | - | - | - | - | 1,971,512,664.21 |
| 非甾体抗炎药物(元) | - | 303,668,616.87 | - | 287,852,563.13 | - |
| 合同定制(元) | - | 4,079,438,603.45 | - | 3,416,507,980.49 | - |
| 抗感染类药物(元) | - | 332,778,980.57 | - | 590,810,301.44 | - |
| 中枢神经类药物(元) | - | 464,471,895.27 | - | 561,263,123.57 | - |
| 降血糖类药(元) | - | 160,187,056.89 | - | 196,763,994.91 | - |
| 新药定制研发和生产服务(CDMO)(元) | 1,970,659,480.91 | - | 2,482,354,923.59 | - | - |
| 营业成本(元) | |||||
| 特色原料药及中间体(元) | 576,545,264.56 | - | 470,499,222.55 | - | 546,701,769.23 |
| 贸易类及其他(元) | 52,772,413.07 | 53,859,114.60 | 68,573,845.18 | 104,201,507.78 | 60,373,878.19 |
| 专利药原料药及中间体(元) | - | - | - | - | 1,182,793,604.62 |
| 非甾体抗炎药物(元) | - | 168,076,810.85 | - | 184,576,756.67 | - |
| 合同定制(元) | - | 2,433,952,057.31 | - | 2,060,544,641.01 | - |
| 抗感染类药物(元) | - | 280,340,363.04 | - | 494,514,313.48 | - |
| 中枢神经类药物(元) | - | 260,674,101.35 | - | 303,957,843.43 | - |
| 降血糖类药(元) | - | 136,862,862.61 | - | 154,664,215.26 | - |
| 新药定制研发和生产服务(CDMO)(元) | 1,161,589,442.50 | - | 1,465,693,820.50 | - | - |
| 毛利(元) | |||||
| 特色原料药及中间体(元) | 154,986,887.65 | - | 222,596,179.19 | - | 230,881,649.62 |
| 贸易类及其他(元) | 9,315,774.12 | 11,429,470.90 | 10,618,351.58 | 23,410,861.68 | 12,408,351.56 |
| 专利药原料药及中间体(元) | - | - | - | - | 788,719,059.59 |
| 非甾体抗炎药物(元) | - | 135,591,806.02 | - | 103,275,806.46 | - |
| 合同定制(元) | - | 1,645,486,546.14 | - | 1,355,963,339.48 | - |
| 抗感染类药物(元) | - | 52,438,617.53 | - | 96,295,987.96 | - |
| 中枢神经类药物(元) | - | 203,797,793.92 | - | 257,305,280.14 | - |
| 降血糖类药(元) | - | 23,324,194.28 | - | 42,099,779.65 | - |
| 新药定制研发和生产服务(CDMO)(元) | 809,070,038.41 | - | 1,016,661,103.09 | - | - |
| 毛利率(%) | |||||
| 特色原料药及中间体(%) | 21.19 | - | 32.12 | - | 29.69 |
| 贸易类及其他(%) | 15.00 | 17.51 | 13.41 | 18.35 | 17.05 |
| 专利药原料药及中间体(%) | - | - | - | - | 40.01 |
| 非甾体抗炎药物(%) | - | 44.65 | - | 35.88 | - |
| 合同定制(%) | - | 40.34 | - | 39.69 | - |
| 抗感染类药物(%) | - | 15.76 | - | 16.30 | - |
| 中枢神经类药物(%) | - | 43.88 | - | 45.84 | - |
| 降血糖类药(%) | - | 14.56 | - | 21.40 | - |
| 新药定制研发和生产服务(CDMO)(%) | 41.06 | - | 40.96 | - | - |
| 收入构成(%) | |||||
| 特色原料药及中间体(%) | 26.46 | - | 21.30 | - | 27.56 |
| 贸易类及其他(%) | 2.25 | 1.21 | 2.43 | 2.46 | 2.58 |
| 专利药原料药及中间体(%) | - | - | - | - | 69.87 |
| 非甾体抗炎药物(%) | - | 5.62 | - | 5.56 | - |
| 合同定制(%) | - | 75.46 | - | 65.95 | - |
| 抗感染类药物(%) | - | 6.16 | - | 11.40 | - |
| 中枢神经类药物(%) | - | 8.59 | - | 10.83 | - |
| 降血糖类药(%) | - | 2.96 | - | 3.80 | - |
| 新药定制研发和生产服务(CDMO)(%) | 71.29 | - | 76.27 | - | - |
| 毛利构成(%) | |||||
| 特色原料药及中间体(%) | 15.92 | - | 17.81 | - | 22.37 |
| 贸易类及其他(%) | 0.96 | 0.55 | 0.85 | 1.25 | 1.20 |
| 专利药原料药及中间体(%) | - | - | - | - | 76.43 |
| 非甾体抗炎药物(%) | - | 6.54 | - | 5.50 | - |
| 合同定制(%) | - | 79.41 | - | 72.19 | - |
| 抗感染类药物(%) | - | 2.53 | - | 5.13 | - |
| 中枢神经类药物(%) | - | 9.84 | - | 13.70 | - |
| 降血糖类药(%) | - | 1.13 | - | 2.24 | - |
| 新药定制研发和生产服务(CDMO)(%) | 83.12 | - | 81.34 | - | - |